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The integration of vascular structures into in vitro
cultured tissues provides realistic models of com-
plex tissue-vascular interactions. Despite the inci-
dence and impact of muscle-wasting disorders,
advanced in vitro systems are still far from reca-
pitulating the environmental complexity of skeletal
muscle. Our model comprises differentiated human
muscle fibers enveloped by a sheath of human mus-
cle-derived fibroblasts and supported by a vascular
network with mural-like cells. Here, we demonstrate
the induction of muscle-specific endothelium and
the self-organization of endomysial muscle fibro-
blasts mediated by endothelial cells. We use this
model to mimic the fibrotic environment character-
izing muscular dystrophies and to highlight key
signatures of fibrosis that are neglected or underes-
timated in traditional 2D monocultures. Overall, this
vascularized meso-scale cellular construct finely
recapitulates the human skeletal muscle environ-
ment and provides an advanced solution for in vitro
studies of muscle physiology and pathology.
INTRODUCTION
With muscle-wasting disorders currently representing a signifi-
cant healthcare burden (Beaudart et al., 2014; Ryder et al.,
2017), the search for effective reparative strategies still requires
faithful in vitro models that include key physiological and
pathological features. In this scenario, the integration of vascular
structures andmesenchymal compartments into in vitro cultured3858 Cell Reports 25, 3858–3868, December 26, 2018 ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://tissues is of paramount importance, not only to ultimately engi-
neer effective tissue constructs capable of integrating within a
host body but also provide realistic models of complex interac-
tions taking place in tissues of interest (e.g., angiogenesis or
vasculogenesis in physiological or pathological tissues, tissue
remodeling, and fibrosis) (Bersini et al., 2016b). As suggested
by a recent investigation in mice, the endothelium displays or-
gan-specific phenotype and architecture (Nolan et al., 2013)
and takes part in the generation of vascular niches that secrete
angiocrine factors involved in organ regeneration, homeostasis,
and metabolism (Rafii et al., 2016). This often underestimated
vessel-type and organ-specific differentiation of endothelial cells
(ECs) has critical implications for understanding tissue develop-
ment and homeostasis, as well as the onset of pathological con-
ditions (Augustin and Koh, 2017; Potente and Ma¨kinen, 2017).
It is widely accepted that vascularized tissue models have
more similarity with in vivo conditions and that tissue growth
and maturation are deeply influenced by the presence of
vasculature (Novosel et al., 2011). In skeletal muscles, vascular
networks of ECs intertwine with bundled multinucleated muscle
fibers (tens of microns in diameter) to ensure blood supply
throughout muscle fascicles. Mesenchymal compartments
also play crucial roles in tissue disease and homeostasis. In skel-
etal muscles, the mesenchymal compartment is constituted by
muscle-supporting cells (fibroblasts and satellite cells) enclosed
in a connective tissue sheath that coversmuscle fibers (endomy-
sium). This structure plays an important role in myogenesis and
the regulation of tissue repair (Mathew et al., 2011; Murphy
et al., 2011), and the cell types included represent major targets
in regenerative therapies for muscle-wasting disorders (Yin et al.,
2013) or pathological tissue remodeling (Mann et al., 2011). For
instance, muscle diseases such as dystrophies crucially involve
muscle fibroblasts and satellite cells that undergo progressive
cycles of degeneration-regeneration, unbalance the productionuthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
of matrix proteins, and lead to abnormal replacement of muscle
fibers with connective tissue containing collagen type I and fibro-
nectin (Klingler et al., 2012; Zanotti et al., 2016). In this context,
Duchenne muscular dystrophy (DMD) is a serious muscle-
wasting disease caused by a mutation of the dystrophin gene
on the X chromosome. The incidence of DMD is approximately 1
in 3,500 male newborns (Carnio et al., 2011). Although treat-
ments aimed at improving patients’ quality of life have been
developed, there is still no effective cure and the median survival
is <30 years (Rall andGrimm, 2012). Several works recently high-
lighted the importance of studying the cross-talk amongmultiple
components of dystrophic muscles, emphasizing how targeting
different cell types, including fibroblasts and ECs, would be
fundamental to effectively address DMD (Shimizu-Motohashi
and Asakura, 2014). In this framework, there is an increasing
need for accurate in vitromodels tailored to muscle pathologies.
Research on dystrophies is widely based on animal models such
as the mdx mouse, without a reliable human in vitro counterpart,
except for simplistic bidimensional cultures of cells.
Attempts at biofabricating skeletal muscle tissues by co-
culturing muscle cells and ECs have been reported (Visone
et al., 2016). Tissue patches generated by co-culturing mouse
myoblasts and ECs within an unarranged 3D matrix were shown
to exhibit vessel-like structures (Levenberg et al., 2005; Shanda-
lov et al., 2014; Perry et al., 2017). Endothelial cords surrounded
by muscle bundles were obtained through microgrooved
collagen scaffolds (Chen et al., 2017). Unorganized lumen struc-
tures were identified in 3D co-cultures of muscle cells and ECs
(Carosio et al., 2013; Gholobova et al., 2015, 2018). Similar re-
sults were recently achieved by embedding, in a fibrin hydrogel
under tension isogenic ECs, pericytes and myogenic cells ob-
tained from human induced pluripotent stem cells (Maffioletti
et al., 2018). Furthermore, perfusable microvascular networks
of human ECs co-cultured with mouse myoblasts were devel-
opedwithin 3D hydrogels (Jeon et al., 2014, 2015). Thesemodels
were not able to replicate the overall complexity of skeletal mus-
cle. In fact, these approaches lack similarity with the human
physiological tissue architecture, where the muscle compart-
ment is organized into long fascicle-like structures intertwined
with a vascular network and an extracellular matrix (ECM)-
depositing mesenchymal tissue. Moreover, no in vitro model
succeeded in demonstrating the organ specificity of the endo-
thelium, a feature until now only described by an in vivo study
in mice (Nolan et al., 2013). For these reasons, there is an urgent
requirement for reliable models recreating a true skeletal muscle
environment that combines proper muscle tissue organization,
matrix-depositing mesenchymal cells, and organ-specific endo-
thelial signatures in a human 3D context. The development of
such a complex environment is necessary to analyze the hetero-
geneous interactions occurring among multiple cell types, which
contribute to skeletal muscle tissue homeostasis and disorders.
Here, we describe the achievement of mesoscale skeletal
muscle 3D constructs embedding differentiated muscle
fibers and vascular networks exhibiting endothelial phenotypic
specificity to muscle tissue. We demonstrate how this multi-
cellular environment interacts with cells of mesenchymal origin.
In particular, vascular networks mediate the recruitment of fibro-
blasts specifically derived from human muscles toward musclefibers. Finally, we analyze matrix deposition by muscle fibro-
blasts derived from patients with DMD, highlighting through
our model differences that were not detectable in traditional 2D
assays.
RESULTS
Formation of Vascular Networks and Mature Muscle
Fibers
Mesoscale systems were previously used for developing vascu-
larized matrices (Underwood et al., 2014), including bone-
mimicking tissue constructs (Bersini et al., 2016a; Bongio et al.,
2016; Arrigoni et al., 2016). Our mesoscale system enables the
casting of three non-planar fibers (600 mm diameter) of differenti-
ated human muscle cells next to one another (600 mm distance
between fibers) and the subsequent addition of hydrogels with
embedded human ECs and supporting mesenchymal cells sur-
rounding the fibers (Figures 1A–1C). More in detail, three muscle
fibers were seeded by injecting human myoblasts embedded in
human fibrin gel inside three cylindrical cavities formed in a sacri-
ficial gel (Figure 1C). After sacrificial gel removal, suspended
muscle fibers were differentiated for 5 days, allowing myoblast
fusion into myotubes. For the vascular compartment, ECs were
embedded in a fibrin-based hydrogel and pipetted inside the
arch-shaped 3D structure surrounding the threemuscle fibers af-
ter 5 days of differentiation. ECswere allowed tomature and orga-
nize in a microvascular network for an additional 3 or 6 days.
Mesenchymal cells supporting the network partially differentiated
into mural-like cells (Figure S1). Computational simulations of ox-
ygen consumption-diffusion in the construct suggested that the
oxygen level within the arch-shaped structure was above the crit-
ical threshold for cell survival (Carreau et al., 2011) (Figure 1B).
Muscle fibers underwent compaction from 600 mm diameter
(hole dimension) to 137 ± 7 mm diameter after 5 days (Figure 2A).
To demonstrate the compatibility with long-term culture, we
analyzed muscle fibers up to day 34, highlighting an additional
step of compaction compared to day 5 (68 ± 3 mm versus
137 ± 7 mm diameter). Viability for long-term culture was proved
by LIVE (green)/DEAD (red) imaging after 34 days of culture (Fig-
ure 2B). As shown by histological sections, the bundle architec-
ture (Figure 2C) more closely resembles the structure of the
native muscle (Figure 2D) compared to muscle cells homoge-
neously embedded in a fibrin matrix (Figure 2E). Muscle fiber dif-
ferentiation was demonstrated by the presence of terminally
differentiated myotubes that were uniformly positive for myosin
heavy chain (MHC) (Figures 2F and 2G), dystrophin, and alpha
actinin (Figure S2). The calculated fusion index was equal to
50% ± 8%. Finally, we performed enzymatic digestion of tissue
constructs, cell sorting, and cell-type-specific gene expression
analysis to evaluate the phenotypic features of muscle fibers.
More in detail, we carried out qRT-PCR analyses of genes
relevant for basic muscular phenotype (desmin and myogenin
factor 5 [MYF5]) (Figure 2H). The expression of these genes in
the muscle cell population was compared to cultures of differen-
tiated muscle cells alone (2D monocultures) or 2D co-cultures
of ECs and differentiated muscle cells. The presence of ECs
significantly increased the expression of desmin in muscle
cells from 2D co-cultures compared tomuscle cell monoculturesCell Reports 25, 3858–3868, December 26, 2018 3859
Figure 1. Design and Biofabrication of 3D Vascularized Muscle Model
(A) 3D graphics of skeletal muscle cellular architecture (left) with muscle cells arranged in packed muscle fibers intertwined with endothelial cells (ECs) forming
blood capillaries. Mural cells support vascular structures, whereas fibroblasts are located in a connective sheath around muscle fibers. (Right) Target config-
uration of our human 3D vascularized muscle model. Three human differentiated muscle fibers are formed in a 3D hydrogel matrix (red) encased in a 3D printed
arch-shaped mask (white) and surrounded by human endothelial microvascular networks. These networks are supported by human bone marrow-derived
mesenchymal stem cells (MSCs) differentiated into mural cells and by human muscle-derived fibroblasts.
(B) Numerical simulation of oxygen consumption-diffusion within the 3D vascularized muscle model. Values of oxygen concentration within both hydrogel and
muscle fibers are maintained above the critical threshold (0.052 mmol/mL) for cell survival.
(C) 3D vascularized muscle model seeding procedure: three steel rods are inserted in the arch-shaped structure side holes (scale bar, 2 mm) and used to cast
three cylindrical cavities in gelatin sacrificial gel (day 0; gelatin colored with red dye for imaging purposes; white arrowheads indicate cylindrical cavities). High-
density human muscle cells are injected in the cavities, gelatin is dissolved, and suspended muscle fibers (black arrowheads) are allowed to differentiate for
5 days (the cell culture medium appears pink in the image). Finally, human EC-laden fibrin gel is pipetted into the central structure gap to surround the three fibers.
After 3 days of maturation vascular networks are formed and surround muscle fibers (day 8; scale bar, 500 mm).
Representative images obtained from >200 independent samples. See also Figure S1.(p < 0.001). The expression of desmin was even higher in muscle
cells from 3D co-cultures compared to 2D co-cultures (p = 0.01),
indicating an additive effect due to the dimensionality of the sys-
tem. However, the expression of MYF5 was not affected either
by the presence of ECs or the dimensionality of the system.
Overall, these results show that the co-culture of muscle cells
with ECs positively influences muscle differentiation (analysis
performed at day 8).
After the addition andmaturation of ECs, the resulting 3D con-
structs were characterized by means of confocal imaging. ECs
developed a network (Figures 3A and 3B) of microvessels (Fig-
ure 3C), which wrapped and connected to muscle fibers (Fig-
ure 3D; Video S1), hence recapitulating the in vivo architecture
of themuscle tissue, where capillary structures intertwine among
single muscle fibers. Overall, the model presented here clearly3860 Cell Reports 25, 3858–3868, December 26, 2018shows that vessels rapidly organize into interconnected micro-
vascular networks with lumen-like structures (Figure 3C), which
not only passively surround muscle fibers but also connect
to and align on their surface (Figure 3D). Co-culturing ECs
with non-bundled, randomly distributed muscle cells in a fibrin
hydrogel only led to the formation of sparse and disconnected
branches of microvessels (Figure S3).
To evaluate the role of mesenchymal cells in interacting with
the microvascular network, ECs were mixed with either human
bone marrow-derived mesenchymal stem cells (MSCs) or mus-
cle-derived human fibroblasts. Parameters of vascular networks
(total network length, diameter, and area covered) found
near muscle fibers (600 3 600 mm2 regions centered on muscle
fibers) and quantified from confocal images (Figures 3E and S4)
demonstrated that MSCsmodified network properties mainly by
Figure 2. Characterization of the Muscle Compartment
(A) Compaction of muscle fibers with time. From a starting diameter of 600 mm, human muscle cells progressively compact the matrix and exhibit diameters of
approximately 140 mm (day 5) and 70 mm (day 34). Data collected from at least three independent experiments. ANOVA test performed to quantify statistical
differences.
(B) LIVE/DEAD staining of muscle fibers demonstrating cell viability for long-term culture (day 34). Viable cells appear in green. No dead cells (red signal) are
detected. Scale bars, 100 mm.
(C–E) Histological sections of different 3D organizations of muscle cells. 3D in vitro muscle fibers (C) show aligned and elongated myotubes more closely
resembling the in vivo architecture (D) compared to muscle cells homogeneously embedded and differentiated in a 3D fibrin hydrogel (E).
(F) Muscle fiber differentiation evaluated by immunostaining for myosin heavy chain (MHC, pink). Muscle fibers exhibit myotubes uniformly positive for MHC.
Green, ECs.
(G) Long-term cultured muscle fibers (red, actin) showing positive MHC immunostaining (green), an indication of muscle differentiation.
(H) Gene expression analyses performed on muscle cells (desmin and MYF5). Fold increase relative to housekeeping gene RPL32 versus 2D muscle cell culture
only.
Gene expression data were obtained from three independent experiments. Unpaired t test was performed to quantify statistical differences. Scale bars, 100 mm
(except 50 mm for G). Error bars represent SEMs. *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S2.narrowing vessel diameters. The length/diameter ratio was
significantly higher in the presence of MSCs with respect to
ECs networks without MSCs (330.2 ± 30.2 versus 228.3 ± 3.9;
p < 0.001 [day 11]) (Figure 3E). However, muscle-derived fibro-
blasts succeeded in populating the constructs while maintaining
stable vascular network parameters. No statistical differences
were found in length/diameter ratio values in constructs seeded
with ECs only and ECs mixed with muscle-derived fibroblasts
(day 11). In addition, the area covered by vascular networks in
the presence of muscle-derived fibroblasts increased from day
8 to day 11. The area covered was lower compared to vascular
networks with MSCs (day 11), although without a statistical dif-
ference (Figure 3E).
Vascular Networks Acquire Organ-Specific Phenotypic
Signature
A recent study has shown that in vivo endothelia are character-
ized by organ-specific genotypic and phenotypic signaturesthat drive important organotypic features of the vascular
compartment (e.g., expression of specific genes and proteins,
fenestrations, junctions, network sizes) (Nolan et al., 2013). To
date, none of the approaches aimed at forming vascularized
models successfully reproduced organ-specific ECs in vitro.
To evaluate phenotypic features of ECs, we performed enzy-
matic digestion of tissue constructs, cell sorting, and cell-type-
specific gene expression analysis. As a first step, we performed
qRT-PCR analyses of genes relevant for endothelial phenotypes
(CD36, CD31) (Figure 4A). These genes were consistently ex-
pressed by ECs cultured in the 3D vascularized muscle model,
with levels of expression comparable to 3D EC monocultures
(CD36) and even higher (CD31, p < 0.05) (Figure 4A), demon-
strating that the presence of muscle cells did not negatively
influence the expression of endothelial-specific genes. Primary
human ECs from muscle biopsies were used as an additional
control, showing similar values of CD31 gene expression when
compared with 3D EC monocultures. The expression level ofCell Reports 25, 3858–3868, December 26, 2018 3861
Figure 3. Confocal Imaging and Characterization of the 3D Vascularized Muscle Model
(A) Confocal reconstruction of the whole system embedding muscle cells (red, actin staining) and ECs (green). ECs self-organize in a uniform vascular network
enclosing the three muscle fibers.
(B) 3D skeletonization of the microvascular network surrounding a muscle fiber. Muscle cells (red, actin staining) and ECs (green).
(C) Microvessels show lumen-like structures. Top view of representative microvessels and confocal reconstruction of the cross-section showing how ECs form
hollow vessels with lumens (white arrowheads). Muscle cells (red, actin staining) and ECs (green).
(D) Detailed imaging of the contact between ECs and muscle cells in the vascularized muscle construct. Muscle fibers (red, actin) wrapped by microvessels
(green, ECs) showing ECs-muscle contacts (white arrowheads) from top view (left) and reconstructed cross-section (right).
(E) Histogram graphs of network parameters (area coverage and length/diameter ratio) quantified from images of vascular networks at day 11 under different
co-culture conditions with muscle cells (ECs, ECs +muscle-derived fibroblasts, ECs +mesenchymal stem cells [MSCs]). ANOVA test was performed to compare
conditions.
Network parameters extracted from at least three independent experiments. Scale bars, 100 mm. Error bars represent SEMs. **p < 0.01, ***p < 0.001.
See also Figures S3 and S4.CD36 resulted higher in primary muscle ECs compared to in vitro
cultured ECs (Figure 4A).
In addition, we quantified the expression of genes peculiar
to in vivo muscle-specific ECs (tetraspanin 7 [TSPAN7] and
peroxisome proliferator-activated receptor gamma [PPARG])
(Figure 4A). Primary ECs extracted from human muscle biopsies
exhibited high levels of TSPAN7 (genetic footprint of muscle-
derived ECs) compared to 3D EC monocultures, as expected.
The expression level of TSPAN7 was also significantly upregu-
lated in the 3D vascularized muscle model compared to 3D EC
monocultures (p < 0.05; Figure 4A). PPARG was also upregu-
lated in ECs collected from the 3D vascularized muscle model
compared to 3D EC monocultures (p = 0.09; Figure 4A), recapit-
ulating differences observed in mice by Nolan et al. (2013). How-
ever, it should be considered that our analyses of human primary
ECs from muscle biopsies showed lower values of PPARG3862 Cell Reports 25, 3858–3868, December 26, 2018compared to ECs from the 3D vascularized muscle model. Addi-
tional microarray analyses were performed to compare the gene
expression of primary ECs extracted from muscle biopsies and
ECs from the 3D vascularized muscle model. We found that
key genes characterizing the muscle specificity of ECs (Nolan
et al., 2013) were not differentially expressed in the two groups
(log2FC > 1 or log2FC < 1, adjusted p value < 0.01; Table S1).
These genes include TSPAN7 and also fetal liver kinase-1
(FLK1), laminin subunit alpha-4 (LAMA4), fibroblast growth fac-
tor-9 (FGF9), activating transcription factor-3 (ATF3), T-box tran-
scription factor-3 (TBX3), phosphatidate cytidylyltransferase 1
(CDS1), ETS domain-containing protein Elk-3 (ELK3), and
C-X-C chemokine receptor type 7 (CXCR7). These data show
that data co-culture with muscle cells is able to initiate a differ-
entiation program leading to muscle-specific endothelia. Based
on this microarray analysis, we selected four genes that are
Figure 4. Characterization of the Vascular Compartment
(A) Gene expression qRT-PCR analyses performed on ECs (CD36, CD31, TSPAN7, and PPARG) isolated from ECsmonocultured in 3D, from the 3D vascularized
muscle model, and from ECs derived from human muscle biopsies. Fold increase relative to housekeeping gene RPL32 versus 3D EC monoculture. Gene
expression data were obtained from three independent experiments. ANOVA test was performed to quantify statistical differences.
(B) 3D vascularized muscle model showing the presence of TSPAN7+ ECs (red) in contact with the muscle fiber. Green, ECs; white, actin; blue, nuclei.
(C) TSPAN7 expression quantified through immunofluorescence within monolayers of ECs incubated with muscle cell conditioned medium or control medium
(no stimuli). Scale bars, 50 mm.
Data obtained from four independent samples. Unpaired t test was performed to compare conditions. Error bars represent SEMs. *p < 0.05, **p < 0.01.
See also Figures S5 and S6.typical of EC muscle-specific differentiation and compared their
expression at the protein level in undifferentiated EC monocul-
tures versus ECs co-cultured with muscle cells. Our data clearly
show a significant increase in these target proteins in the EC
population upon co-culture with muscle cells (Figure S5).
Finally, we found TSPAN7+ ECs in immunofluorescent images
of the 3D vascularized muscle model. In particular, we identified
the brightest cells in close proximity to muscle fibers (Figure 4B).
We hypothesize that the muscle-induced expression of TSPAN7
is at least in part related to cell-cell paracrine interactions
and gradients of muscle-secreted molecules. We found that
EC monolayers treated with muscle cell conditioned media
were characterized by higher TSPAN7 expression compared to
ECs treated with control medium (‘‘no stimuli’’) (490 ± 11 versus
410 ± 2) (Figure 4C).
ECs Mediate the Recruitment of Muscle-Specific
Fibroblasts
To investigate potential effects due to the presence of ECs in our
3D construct, we mixed muscle-derived human fibroblasts with
ECs. Homogeneously distributed muscle-derived human fibro-
blasts progressively migrated toward muscle fibers (day 8) and
finally adhered to the outer part of the fibers generating a sheath
(day 11) (Figure 5A), which resembled the in vivo localization
of the connective endomysium (Agley et al., 2013). Of note,
this fibroblasts-muscle fiber interaction was not observed inconstructs embedding lung-derived fibroblasts in the presence
of ECs (Figure 5B) or in constructs embedding muscle-derived
fibroblasts without ECs (Figure 5C). The area covered by muscle
fibroblasts in vascularized constructs was significantly higher
compared to the area covered by lung fibroblasts in vascularized
tissue constructs (95.1% ± 2.3% versus 8.98% ± 3.15%) or by
muscle fibroblasts in avascular tissue constructs (95.1% ±
2.3% versus 16.12% ± 4.72%) (Figure 5D). Overall, these data
demonstrate that ECs are critical for recreating specific cellular
interactions and physiological cross-talk in tissue-like models.
DMD-Derived Muscle Fibroblasts Show Increased
Matrix Deposition in Vascularized Muscle Constructs
Compared to Standard Culture
Muscular dystrophies including DMD are characterized by an
unbalanced production of matrix proteins that leads to the
abnormal replacement of muscle fibers with connective tissue.
At present, no in vitromodel is able to reliably analyze the depo-
sition of ECM proteins, with the exception of simplistic bidimen-
sional cultures.
For this reason, we challenged the 3D vascularized muscle
model with pathological conditions by embedding in the 3D con-
structs muscle fibroblasts derived from a single DMD patient,
rather than from a healthy subject (no changes were introduced
for the other components of the model). Fibroblasts are mainly
responsible for the deposition of ECM components. Hence, weCell Reports 25, 3858–3868, December 26, 2018 3863
Figure 5. Fibroblast Recruitment to Muscle Fibers
(A) Distribution of human muscle-derived fibroblasts in the 3D vascularized muscle model at days 8 and 11. Vybrant cell labeling was used to specifically track
human muscle-derived fibroblasts (white). Actin staining (red) highlights all of the cell populations, including differentiated muscle fibers, while ECs are shown in
green.
(B) Human lung-derived fibroblasts recruitment in the 3D vascularized muscle model.
(C) Distribution of human muscle-derived fibroblasts in the 3D muscle model without ECs.
(D) Quantification of fibroblast recruitment in the conditions shown in (A), (B), and (C).
Scale bar, 100 mm.Data obtained from at least three independent experiments. ANOVA test was performed to quantify statistical differences. Error bars represent
SEMs. ***p < 0.001.hypothesized that introducing pathological fibroblasts without
changes in other components of the systems would have al-
lowed the reproduction of key features of fibrosis observed
in vivo. In parallel, we stimulated healthy 3D vascularized muscle
constructs with 10 ng/mL transforming growth factor beta 1
(TGF-b1), a known inducer of fibrotic responses in fibroblasts
of different origin and generally used as the gold standard for
mimicking tissue fibrosis in cell cultures (Zanotti et al., 2016).
The main goal of the following analysis was to study how
different cell types (e.g., healthy fibroblasts, TGF-b1-treated fi-
broblasts, DMD fibroblasts) deposit ECM proteins and demon-
strate that the 3D vascularizedmusclemodel could be effectively
used to investigate fibrosis. Collagens and fibronectin represent
major components of fibrotic matrices. In addition, dystrophic
muscles are characterized by the presence of myofibroblasts
whose main marker is a-smooth muscle actin (Wynn, 2008).
For this reason, we decided to analyze and compare the
presence of these markers in each experimental condition.
The expression of collagen I in vascularized muscle tissues
containing DMD fibroblasts was significantly higher compared
to both control (p < 0.001) and TGF-b1-treated samples
(p < 0.001) (Figures 6A and 6B). In a similar way, tissue
constructs with embedded DMD fibroblasts highlighted a
significantly higher level of fibronectin compared to control
(p < 0.001) and TGF-b1-treated (p < 0.001) samples (Figures
6A and 6B). Moreover, DMD fibroblasts showed higher expres-3864 Cell Reports 25, 3858–3868, December 26, 2018sion of a-smooth muscle actin compared to control fibroblasts
(p < 0.001), which is an indication of differentiation toward a
pathological myofibroblast condition (Figures 6A and 6B). These
results demonstrate that the 3D vascularized muscle model
with embedded pathological fibroblasts is able to recapitulate
the upregulation of key markers of fibrosis. The DMD fibroblasts
secreted even more collagen I and fibronectin compared to
tissue constructs treated with TGF-b1, which is considered the
optimal treatment to induce tissue fibrosis in vitro.
The same analyses were performed in 2D models, based on
the co-culture of ECs and fibroblasts on top of monolayers of
differentiated muscle cells. Fibroblast monocultures or co-cul-
tures of muscle cells and fibroblasts (without ECs) represent
the gold standard in current muscle fibrosis experiments. No
clear differences were observed in terms of matrix deposition
between DMD and control fibroblasts. Collagen I expression
only showed a positive trend in DMD fibroblasts compared to
control cells (Figures 6C and 6D). A similar trend was quantified
for a-smoothmuscle actin, even though no statistical differences
were detected (Figures 6C and 6D). Hence, these results did
not replicate differences observed through the 3D vascularized
muscle model. In addition, in contrast to 3D experiments,
the a-smooth muscle actin content was significantly higher
in TGF-b1-treated samples compared to DMD fibroblasts
(p < 0.05). Finally, the amount of fibronectin in DMD and control
samples was comparable (Figures 6C and 6D).
Figure 6. Application of the 3D Vascularized Muscle Model for the Study of Fibrosis
(A and B) Confocal imaging (A) and quantification (B) of fibrotic markers (green, a-smooth muscle actin, collagen I, and fibronectin) in the 3D model with
embedded control (ctrl) fibroblasts, Duchenne fibroblasts, or TGF-b1-treated fibroblasts (white, Vybrant cell labeling to specifically track fibroblasts). Red, ECs;
blue, nuclei.
(C and D) Confocal imaging (C) and analysis (D) of fibrotic markers in the 2D model.
Scale bars, 100 mm. Data obtained from at least three independent experiments. ANOVA test was performed to quantify statistical differences. Error bars
represent SEMs. *p <0.05, **p < 0.01, ***p < 0.001.Overall, we have demonstrated that tissue constructs with
embedded DMD fibroblasts are able to secrete key ECM pro-
teins such as collagen I and fibronectin. Furthermore, confocal
imaging revealed that the amount of secreted proteins was
higher with DMD fibroblasts compared to healthy fibroblasts.
Finally, the comparison between our 3D vascularized muscle
model and a simplified 2D co-culture showed that our approach
is able to capture differences that are reduced or even neglected
in traditional 2D models. However, we should also consider
that the cells used here were derived from a single donor and
that further analyses using cells from multiple patients will be
required to confirm the differences between biological groups.
DISCUSSION
The development of complex and faithful pathophysiological
models represents a key challenge to improve the outcome of
basic and translational research. Musculoskeletal tissue has a
distinctive 3D architecture that is characterized by muscle fiberssurrounded by a fibroblast-rich endomysium and intertwined
with microvascular networks. This spatial organization is funda-
mental to maintain the functionality of the muscle tissue and can
be reproduced by advanced 3D models and tissue constructs.
Here, we report a method for biofabricating in vitro 3D human
vascularized skeletal muscle environments that exhibit not only
a more in vivo-like architecture but also fundamental physiolog-
ical features that were previously overlooked. Building on previ-
ous models based on single muscle fibers or sheets (Madden
et al., 2015; Neal et al., 2014), we showed how to include a
self-organizing vascular network that wraps multiple non-planar
differentiated muscle fibers. As demonstrated by the trend of fi-
ber compaction (Figure 2A) and by confocal imaging (Figures 2F,
2G, and S2), the engineered muscle tissue constructs are grad-
ually differentiating toward in vivo-like muscle fibers.
We demonstrated how human ECs forming vascular networks
within the in vitro muscle model are induced to acquire pheno-
typic characteristics of in vivo muscle ECs. This phenotypic
modulation was previously observed only in in vivo experiments,Cell Reports 25, 3858–3868, December 26, 2018 3865
and no other in vitro report addressed the organ or muscle spec-
ificity of ECs. We have preliminarily investigated putative mech-
anisms responsible for this phenotypic change; co-culture of
ECs with muscle cells induced upregulated expression of target
genes (TSPAN7 and PPARG). We hypothesize the existence of a
paracrine action exerted by muscle cells on ECs, as suggested
by an increase in target proteins in ECs cultured with muscle-
conditioned media. Microarray and western blot analyses
confirmed that ECs co-cultured with muscle cells were actually
differentiating toward a muscle-specific endothelial phenotype.
We explored the importance of including the vascular
compartment by analyzing the response of cells ofmesenchymal
origin in our vascularized muscle construct. Human muscle-
derived fibroblasts were embedded in the fibrin gel surrounding
the fibers, together with ECs. This construct formulation allowed
for the vascular network to form without major structural
alterations, as analyzed by network parameters (Figures 3E
and S4). We observed how muscle-derived fibroblasts migrated
toward muscle fibers, forming an enveloping sheath that mimics
the endomysium. Our 3D model allowed us to identify a key
effect of the heterotypic cross-talk among ECs, muscle fibro-
blasts, and muscle cells. We were able to recapitulate the orga-
notypic process driving muscle-specific fibroblast recruitment
toward differentiated muscle fibers, while lung-specific fibro-
blasts were not able tomigrate andwrapmuscle cells. Fibroblast
recruitment was observed only when vasculature was present in
the system, thus demonstrating that introducing a vascular
compartment does not merely represent the attempt to model
a vascularized tissue but has critical consequences on the
physiological behavior of specific cell types. These results also
extend recent findings that vascular cells can increase myogen-
esis and muscle contraction of in vitro-cultured mouse muscle
cells (Osaki et al., 2018).
The behavior of fibroblasts in skeletal muscles is known to play
a key role in muscle-wasting disorders, particularly in the
replacement of functional muscle cells with ECM-based, non-
contractile connective tissue (Grounds, 2008; Zanotti et al.,
2016). Conventional 2D assays are generally limited to the study
of the intracellular levels of specific proteins (Stahnke et al.,
2017), since the lack of 3D architectural arrangement does not
allow the quantification of the 3D accumulation and the distribu-
tion of proteins in the surrounding environment (Bersini et al.,
2018). In this framework, the lack of a physiological 3D matrix
in which secreted proteins can gradually accumulate could
reduce the differences between experimental groups. Herein,
we have exploited our 3D model to show that the inclusion of
DMD-derived fibroblasts (without changing any other cellular
component of the system) is sufficient to significantly increase
the expression level of fibrosis-associated proteins, such as
collagen I and fibronectin, compared to control or TGF-b1-
treated fibroblasts. We demonstrated that statistical differences
in terms of collagen I, fibronectin, and a-smooth muscle actin
between 3D constructs embedding DMD fibroblasts or control
healthy muscle fibroblasts were not detected in 2D co-culture
experiments. According to conventional 2D assays, TGF-b1 ap-
pears to be in principle a good strategy to mimic pathological
DMD fibroblasts. Our results in terms of a-smooth muscle actin
seem to confirm this assumption. However, the expression of3866 Cell Reports 25, 3858–3868, December 26, 2018collagen I in TGF-b1-treated samples was significantly different
compared to samples with DMD fibroblasts, and no clear differ-
ences were detected in terms of fibronectin. In contrast, our 3D
tissue constructs reveal that the expression of both collagen I
and fibronectin in TGF-b1-treated fibroblasts was significantly
lower compared to DMD fibroblasts (p < 0.001), while no
changes were detected in terms of a-smooth muscle actin. In
addition, clear differences were always detectable when
comparing samples with healthy and DMD fibroblasts. Overall,
we were able to show that DMD fibroblasts embedded in a 3D
vascularized muscle environment recapitulate the abnormal
fibrotic deposition of ECM proteins, including collagen I and
fibronectin. In addition, DMD fibroblasts express a-smoothmus-
cle actin, a key hallmark of differentiation toward a myofibroblast
phenotype. Collected data thus show that traditional 2D assays
may overlook or bias critical aspects of cell behavior that are
instead captured in our 3D vascularized muscle environment.
Future work may be directed to overcome the present limita-
tions of the model. For instance, this system was not specifically
designed to create contractile muscle fibers or to control perfu-
sion through patent vessels. As previously reported by others,
the addition of biochemical (e.g., Matrigel) (Madden et al.,
2015) and biophysical (e.g., electrical field) (Neal et al., 2014)
stimuli is critical to promote muscle fiber contraction. However,
the generation of contractile muscle fibers was not directly
required to reproduce and analyze the heterotypic interactions
among each component of the muscle environment.
In conclusion, we have highlighted evidence of endothelial or-
gan specificity andmuscle-specific fibroblast recruitment, which
were not previously observed in vitro. These results were ob-
tained through a model of vascularized muscle that presents
high levels of similarity with the physiological muscle environ-
ment. The key features of the model—architecture of the system
and multiple players involved—were overlooked by all previous
reports and come together in a comprehensive 3D human vas-
cularized skeletal muscle environment, which is relevant in
exploring muscle fibroblast physiological and pathological
behavior during fibrosis. The model presented here proved to
be compatible not only with high-resolution imaging techniques
and analyses ofmatrix deposition but also with cell-type-specific
mRNA retrieval for in-depth gene expression analyses. It is thus
expected to bring significant advances to basic skeletal muscle
research as well as to the pipeline of drug discovery and/or
screening for muscle disorders.STAR+METHODS
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matteo
Moretti (matteo.moretti@grupposandonato.it).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Human biopsies were obtained after informed consent. The study was approved by the Ethics Committee of Ospedale San Raffaele
(Milan, Italy). Copy of the approval letter is available upon request. Here are detailed information of human donors:
Donor 1: 43 years old, female, Caucasian
Donor 2: 51 years old, male, Caucasian
Donor 3: 46 years old, male, Caucasian
Cell isolation and culture
Immortalized muscle cells were a kind gift of Dr. Gabellini (San Raffaele Hospital). Additional information on the isolation and char-
acterization of muscle cells are available at https://www.umassmed.edu/wellstone as well as in a recent publication by Dr. Gabellini
lab (Ferri et al., 2015). The ‘‘University of Massachusetts Medical School Senator Paul D. Wellstone Muscular Dystrophy Cooperative
Research Center for FSHD’’ is an internationally recognized biobank providing pure populations of muscle cells from healthy and
diseased donors. Muscle cells were grown in muscle growth medium (4:1 DMEM:Medium199, LifeTech, Italy) supplemented with
15% Fetal Bovine Serum (FBS, GE Healthcare Life Sciences, Italy), 2% HEPES (LifeTech), 0.03 mg/ml ZnSO4 (Sigma-Aldrich,
Germany), 1.4 mg/ml vitamin B12 (Sigma-Aldrich), 0.055 mg/ml dexamethasone (Sigma-Aldrich), 1% penicillin/streptomycin/
glutamine (PSG, LifeTech), 1% sodium pyruvate (LifeTech), 2.5 ng/ml hepatocyte growth factor (PeproTech, UK) and 10 ng/ml basic
fibroblast growth factor (PeproTech). For myoblast fusion and differentiation, cells were switched to 4:1 DMEM:Medium199 supple-
mented with 2% FBS, 1% PSG and 1% sodium pyruvate.
ECs were purchased from Angioproteomie (http://www.angioproteomie.com/commerce/ccc2444-human-endothelial-cells-
normal-human-endothelial-cells–human-lymphatic-endothelial-cells–stable-shrna-transfected-huvecs.htm), which is a company
specialized in the isolation and characterization of ECs from different sources and tissues. The company certifies that ECs are
CD31 and vascular endothelial (VE)-cadherin positive. These markers are recognized as critical indicators for EC identity. ECs
were cultured in endothelial growth medium-2 (Lonza, distributed in Italy by Euroclone) up to passage 7. Primary ECs from muscle
biopsies were isolated from patients undergoing hip surgery following informed consent. Cells were selected for the expression of
CD31 and cultured in EGM-2 (Lonza).
Human bone-marrow derivedmesenchymal stem cells (MSCs) were collected from bone-marrow aspirates of patients undergoing
hip surgery following informed consent. MSCswere selected by plastic adherence and used up to passage 6 (Jeon et al., 2015). Cells
were cultured using a-MEM (LifeTech) supplemented with 10% FBS, 1% penicillin/streptomycin, 1% HEPES, 5 ng/ml basic fibro-
blast growth factor.
Fibroblasts (control and DMD) were isolated from tissue biopsies based on previously established protocols (Zanotti et al., 2011,
2013). Briefly, fibroblasts were isolated from connective tissue chunks of muscle biopsies. Connective tissue was minced in small
pieces and plated on standard plastic dishes. Outgrowth cells were collected and expanded up to passage 4. Muscle fibroblasts
were cultured using DMEM supplemented with 10% FBS, 1% penicillin/streptomycin and 5 ng/ml basic fibroblast growth factor.




Arch-shaped 3D structureswere fabricated by 3D printing of Clear Resin Formlabs (Formlabs Inc., USA). The gap size within the arch-
shaped structure was 2x2x4 mm3 (2x2 mm2 is the cross-sectional area). Cells were embedded within this gap size. This 2x2x4 mm3
gap was encased in a structure whose dimension was 5x4x4 mm3. The diameter of the side through-holes was 600 mm. The struc-
tures were irreversibly glued to a glass coverslip and sterilized with iso-propanol before use.
Computational simulations
The oxygen consumption-diffusion wasmodeled with Comsol Multiphysics. Themodel considered the presence of a 3D fibrin matrix
embedding ECs and 3 fibers of muscle cells. Cell constructs were modeled with 1,000,000 tetrahedral elements. Atmospheric
oxygen level was assumed at the 2 lateral openings of the 3D arch-shaped structure and at the side through-holes for muscle cell
injection. All other boundaries were assigned as ‘‘no flux’’ boundary conditions in order to reproduce the presence of the oxygen
impermeable arch-shaped structure. The oxygen diffusion coefficient was assumed equal to 2 3 10-9 m2/s (Colom et al., 2014).e2 Cell Reports 25, 3858–3868.e1–e4, December 26, 2018
The oxygen consumption was assumed to be 5.51 3 10-5 mol/(m3 3 s) for ECs (Abaci et al., 2011) and 3.23x10-4 mol/(m3 3 s)
for muscle cells (Motterlini et al., 1998). A Michaelis-Menten kinetics was assumed for ECs considering a Michaelis constant of
5.5x10-4 mol/m3 (Abaci et al., 2011).
3D Construct preparation
Preparation of muscle fibers was performed adapting previously described protocols (Neal et al., 2014). Three steel rods (600 mm
diameter) were first inserted into the three side holes of the 3D arch-shaped structures. A warm solution of porcine skin gelatin
(50 mg/ml, Sigma-Aldrich) in muscle growth medium supplemented with 2.5 mg/ml 6-aminocaproic acid (Sigma-Aldrich) was pipet-
ted in the central frame gap and cooled at 4C for 15’. The steel rods were pulled out of the frame forming three cylindrical cavities in
the cooled gelatin. Highly concentrated humanmyoblasts (20M cells/ml) were 1:1mixedwith a fibrin gel solution (5mg/ml) and imme-
diately injected in the cavities. The gel was allowed to polymerize for 15’ at room temperature. The constructs were then immersed in
1 mL muscle differentiation medium for 5 days to dissolve gelatin and induce myoblast differentiation. A second fibrin gel (5 mg/ml)
was then prepared to surround the differentiated muscle fibers and 1:1 mixed with different cell suspensions: 2.5M cells/ml ECs
alone; 2.5M cells/ml ECs: 0.25M cells/ml MSCs; 2.5M cells/ml ECs: 0.25M cells/ml muscle-derived fibroblasts. The constructs
were dried by pipetting medium out of the central gap and the fibrin gel solution was subsequently injected. The gel was allowed
to polymerize for 15’ at room temperature in humidity chambers. The constructs were then immersed in 1 mL EGM-2 and cultured
for additional 3 or 6 days.
Regarding 3D constructs for muscle monocultures, cells were embedded in the matrix at the same density used for the develop-
ment of the 3Dmuscle fibers (10Mcells/ml). The constructs were then kept in culture for the same amount of time of 3Dmuscle fibers.
Immunofluorescence
Constructs were fixed with 2.5% paraformaldehyde for 30 min. Permeabilization and blocking steps were performed with Triton
X-100 (0.1%) and Bovine Serum Albumin (5%). Cells were then probed with the following primary antibodies (overnight at 4C):
anti-a Smooth Muscle Actin (1:60, mouse anti-human, Abcam, distributed in Italy by Prodotti Gianni) to highlight differentiation of
MSCs into mural cells; anti-Fast Myosin Heavy Chain (1:100, mouse anti-human, Abcam), anti-sarcomeric alpha actinin (1:100,
mouse anti-human, Abcam) and anti-dystrophin (1:100, rabbit anti-human, Abcam) to highlight muscle cells differentiation; anti-Pax7
(1:100, mouse anti-human, Santa Cruz, distributed in Italy by DBA) for satellite cells; anti-collagen type I (1:250, rabbit
anti-human, Abcam) and anti-fibronectin (1:200, rabbit anti-human, Abcam) for ECM protein deposition; anti-TSPAN7 (1:25, rabbit
anti-human, Santacruz) for EC differentiation. Samples were washed with Phosphate Buffered Saline (PBS) and overnight incubated
with secondary antibodies at 4C (Alexa Fluor 488 or Alexa Fluor 568 or Alexa Fluor 647). Vybrant cell labeling (DiD, LifeTech)
was employed to track muscle-derived fibroblasts. Nuclear staining was performed with DAPI whereas actin fibers staining was
performed with Phalloidin.
Image acquisition and analysis
High-resolution images of the constructs were acquired with a two-photon confocal microscope (Nikon A1R MP+ with Coherent
UltraII). Images for vascular network quantifications were acquired with confocal microscope (Leica TCS SP2). Fiji software
(http://fiji.sc/) and Imaris software (Bitplane) were used for image analysis. Imaris software was employed to capture qualitative
images of the vascular network skeleton using the FilamentTracer plugin.
For quantification of fibroblast recruitment, we employed Fiji to design 100 3 100 mm2 regions along multiple fibers collected in
different experiments. We quantified the recruitment as the area fraction covered by fibroblasts (white color in Figure 5) in each
ROI for each different condition. Data were obtained from 3 independent experiments.
Regarding matrix protein deposition in 2D and 3D, we employed Fiji to design 200 3 200 mm2 regions and we quantified the fluo-
rescence intensity of each specific antibody in each ROI for each condition. Data were obtained from 3 independent experiments.
Cell sorting
Hydrogels were digested using 50 U/ml nattokinase (JBSL-USA) under stirring for 30 min at 37C. Next, single cell populations
were sorted. Briefly, cells were incubated with biotinylated anti-CD31 (Abcam) for 10’ at 4C under stirring. Streptavidin coupled
dynabeads (LifeTech) were then added and incubated for 20 min at 4C under stirring. Following interaction with the magnet,
anti-CD31 labeled ECs were collected while muscle cells were obtained from the supernatant. Each cell population was then
used for gene expression analyses.
qRT-PCR and Microarray analyses
Total RNA of each cell population (cells isolated from 3D vascularized muscle models, 3D ECs monocultures, primary ECs from
human muscle biopsies) was extracted by using the PureLink RNA Mini Kit (Ambion, Italy). cDNA was obtained using the iScript
cDNA Synthesis Kit (Bio-Rad, Italy). Gene expression of selected markers was analyzed by qRT-PCR. The following primers were
employed for ECs: CD36, CD31, TSPAN7 and PPARG. Muscle cells were analyzed using the following probes: MYF5 and Desmin.
Details are reported in Figure S6. Three experimental replicates were analyzed for each marker. ECs were analyzed after 3 days
co-culture with muscle cells (or 3 days monoculture for control samples). The gene expression was normalized to the housekeepingCell Reports 25, 3858–3868.e1–e4, December 26, 2018 e3
gene ribosomal protein L32 (RPL32) and to the experimental control (3D ECs monocultures or muscle cells monocultures) using the
2-DDCt method.
Regarding Microarray analyses, total RNA of ECs was extracted following the same procedure described above. Libraries were
then prepared according to the manufacturer protocol (Agilent). The comparison involved 2 independent biological replicates of
ECs after co-culture with muscle cells and 3 different populations of primary muscle-derived ECs from 3 different donors.
Western Blot
ECs were cultured or co-cultured for 3 days and then sorted. The cells were lysed in NP40 buffer, supplemented with a protease
inhibitor cocktail and 1mMphenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich, Saint Louis, MO, USA) for 30min on ice, then centri-
fuged at 13,000 r/min for 10min at 4C, and the supernatant was stored at20C until assayed. Protein content was determined with
the Pierce BCA protein assay (Thermofisher, Waltham, MA, USA). Proteins (15 mg) were loaded on 8% sodium dodecyl sulfate
(SDS)-polyacrylamide gels and then then electroblotted onto Hybond-P polyvinylidene difluoride transfer membranes (BioRad
Laboratories, CA, USA). After blocking (5%non-fat drymilk in PBS, 30min, room temperature), themembraneswere incubated over-
night at 4C with 1:10 rabbit polyclonal anti-human TSPAN7 (sc-139572, Santa Cruz Biotechnology Dallas, TX, USA), 1:100 mouse
monoclonal anti-human FGF-9 (sc-373716, Santa Cruz Biotechnology), 1:200 mouse monoclonal anti-human Flk-1 (sc-6251, Santa
Cruz), 1:1000 mouse monoclonal anti-human Laminin a-4 (MA5-24651, Thermofisher). b-Tubulin I was used as housekeeping by
means of 1:20000 mouse monoclonal anti-human b-Tubulin I (T7816, Sigma-Aldrich), all of them in 5% non-fat dry milk in PBS. After
washing with tween-supplemented tris-buffered saline (TBS-T) 0.3% for 30 min, themembranes were incubated for 1 h at room tem-
perature with a goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated polyclonal antibody (1:5000; A0545; Sigma-Aldrich),
or goat anti-Mouse IgG HRP-conjugated polyclonal antibody (1:5000, 62-6520 Thermofisher), and developed with a chemilumines-
cence enhancement kit (ClarityMaxWestern ECLSubstrate, BioRad, Hercules, CA, USA). Band densities were quantified fromdigital
acquisition by a Chemidoc Imaging System (Biorad) using NIH ImageJ software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unpaired Student’s t test and one-way analysis of variance (ANOVA) were performed using Prism Graph Pad. Data were first
analyzed for normality and then compared with parametric statistics. Differences were considered significant with p < 0.05 (*),
p < 0.01 (**) and p < 0.001 (***). Results are presented asmean ± standard error of themean (SEM). Details are reported in each figure.
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